Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that it will host three events featuring the Company’s lead product, Dermagraft® at this year’s Diabetic Foot Global Conference (DF Con) 2010, the largest annual interdisciplinary diabetic foot conference in North America.
“Delayed Progress in Wound Area Reduction After Four Weeks of Standard Care Predicts Failure to Heal Diabetic Foot Ulcers.”
Dermagraft is an FDA-approved bio-engineered skin substitute that repairs damaged tissue and supports the body’s natural healing process in patients with diabetic foot ulcers (DFUs). DFUs affect 15 to 25 percent of diabetes patients during their lifetime, putting them at risk for lower limb amputation or death if not treated properly. Dermagraft is also the focus of an ongoing pivotal trial in subjects with venous leg ulcers.
DF Con 2010 is focused on bringing together physicians and other clinicians, researchers, scientists, and limb salvage experts committed to improving standards of care in the treatment of DFUs, with the goal of reducing amputations due to the disease.
“There is much work that remains to be done for the treatment of DFUs, but we have already made great strides,” says Dean Tozer, Senior Vice President of ABH. “Through events such as DF Con 2010, we hope to continue to educate medical professionals on ways to effectively manage DFUs and increase patient compliance. Ideally, this will ultimately result in a greater standard of living for these patients and a return to normalcy after their DFU heals.”
ABH will host the following events at DF Con 2010: